Company: CRNX
Filing Date: 2025-12-17
Form Type: 8-K
Source: 0001658247-25-000022
Chunk: 3

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-12-17
Form: 8-K
Item: Item 9.01
Chunk 3
---
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

  Exhibit No.      Description                                                                                                                    
         10.1      Transition and Separation Agreement, dated as of December 16, 2025, between Crinetics Pharmaceuticals, Inc. and Dana Pizzuti.  
         10.2      Advisor Agreement, dated December 16, 2025, between Crinetics Pharmaceuticals, Inc. and Dana Pizzuti.                          
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
          104      Cover Page Interactive Data File (embedded within the Inline XBRL document)                                                    

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

                                             Crinetics Pharmaceuticals, Inc.        
  Date:      December 17, 2025      By:      /s/ R. Scott Struthers, Ph. D.         
                                             R. Scott Struthers, Ph. D.